Injection Lipolysis Comprehensive Study by Drug (Deoxycholic Acid, Phosphatidylcholine, Others), Treatment Type (Facial Fat Deposits, Submental Fat, Upper Arm Fat, Abdominal Fat, Thighs Fat, Knee Fat, Buttock Fat, Others), End User (Hospitals, Dermatology and Cosmetic Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2027

Injection Lipolysis Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Injection Lipolysis?
Injection lipolysis is a controversial cosmetic procedure in which medicate mixtures are infused into patients with the goal of destroying fat cells. It is additionally connected in cosmetic surgeries to the patients to reduce the number of fat cells. Injection lipolysis is a non-surgical alternative in which drug blends such as deoxycholic acid, in combination with vitamin E, l-carnitine, collagenase, isoproterenol, and hyaluronidase are infused to destroy fat cells. In the US and in Canada the only FDA-approved fat dissolving injection is deoxycholic acid and it is indicated only for the treatment of sub mental fat known as the double chin. Injection lipolysis is a method using thin needles injecting into the skin solutions containing substances that break down fats in fat cells. These arrangements usually contain phosphatidylcholine. It is a natural substance, which is obtained from the soybeans but also is naturally in the human body.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledValeant Pharmaceuticals International, Inc. (United States), Allergan plc. (Ireland), Alma Lasers, Ltd. (Israel), Cynosure, Inc. (United States), Sciton, Inc. (United States), Solta Medical Inc. (United States), Lumenis Ltd. (Israel), Syneron Medical Ltd. (United States) and Apollo Cosmetic Clinics (India)


The study covers a detailed analysis segmented by key business segments i.e. and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Injection Lipolysis market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Injection Lipolysis market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Valeant Pharmaceuticals International, Inc. (United States), Allergan plc. (Ireland), Alma Lasers, Ltd. (Israel), Cynosure, Inc. (United States), Sciton, Inc. (United States), Solta Medical Inc. (United States), Lumenis Ltd. (Israel), Syneron Medical Ltd. (United States) and Apollo Cosmetic Clinics (India).

Food and Drug Administration (FDA) Approval: Currently, KybellaTM is the only FDA approved injectable solution for lipolysis. Physicians who wish to use other agents in the literature for adipose reduction may be subject to some degree of liability as the FDA may review individual occurrences on a case-by-case basis for enforcement action.
The companies are exploring the market by adopting expansions, investments, and new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.

Injection Lipolysis Market Dynamics:
AttributesDetails
Growth Drivers
  • Growing Awareness Towards the fat Reduction Process
  • Increasing Population of Obese People
  • Increasing Demand for Non-Invasive Procedures
  • Demand for Cosmetic surgeries
Major Trends
  • Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle
Restraints
  • Side Effects of Treatment
Road Blocks / Challenges
  • High Cost of Treatment
  • Presence of Other Fat Breakdown Techniques
Gaps & Opportunities
  • Rise in Medical Tourism
  • Increase in Adoption of Body Contouring
  • High Market Potential in Untapped Emerging Economies


Key highlights of the Global Injection Lipolysis market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Injection Lipolysis market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Injection Lipolysis market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Injection Lipolysis Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Injection Lipolysis market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Injection Lipolysis market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Raw Material Supliers and End-Use Industries.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Drug
  • Deoxycholic Acid
  • Phosphatidylcholine
  • Others

By Treatment Type
  • Facial Fat Deposits
  • Submental Fat
  • Upper Arm Fat
  • Abdominal Fat
  • Thighs Fat
  • Knee Fat
  • Buttock Fat
  • Others

By End User
  • Hospitals
  • Dermatology and Cosmetic Clinics
  • Ambulatory Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Awareness Towards the fat Reduction Process
      • 3.2.2. Increasing Population of Obese People
      • 3.2.3. Increasing Demand for Non-Invasive Procedures
      • 3.2.4. Demand for Cosmetic surgeries
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Treatment
      • 3.3.2. Presence of Other Fat Breakdown Techniques
    • 3.4. Market Trends
      • 3.4.1. Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Injection Lipolysis, by Drug, Treatment Type, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Injection Lipolysis (Value)
      • 5.2.1. Global Injection Lipolysis by: Drug (Value)
        • 5.2.1.1. Deoxycholic Acid
        • 5.2.1.2. Phosphatidylcholine
        • 5.2.1.3. Others
      • 5.2.2. Global Injection Lipolysis by: Treatment Type (Value)
        • 5.2.2.1. Facial Fat Deposits
        • 5.2.2.2. Submental Fat
        • 5.2.2.3. Upper Arm Fat
        • 5.2.2.4. Abdominal Fat
        • 5.2.2.5. Thighs Fat
        • 5.2.2.6. Knee Fat
        • 5.2.2.7. Buttock Fat
        • 5.2.2.8. Others
      • 5.2.3. Global Injection Lipolysis by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Dermatology and Cosmetic Clinics
        • 5.2.3.3. Ambulatory Surgical Centers
      • 5.2.4. Global Injection Lipolysis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Injection Lipolysis (Price)
  • 6. Injection Lipolysis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Valeant Pharmaceuticals International, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan plc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Alma Lasers, Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cynosure, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sciton, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Solta Medical Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lumenis Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Syneron Medical Ltd. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apollo Cosmetic Clinics (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Injection Lipolysis Sale, by Drug, Treatment Type, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Injection Lipolysis (Value)
      • 7.2.1. Global Injection Lipolysis by: Drug (Value)
        • 7.2.1.1. Deoxycholic Acid
        • 7.2.1.2. Phosphatidylcholine
        • 7.2.1.3. Others
      • 7.2.2. Global Injection Lipolysis by: Treatment Type (Value)
        • 7.2.2.1. Facial Fat Deposits
        • 7.2.2.2. Submental Fat
        • 7.2.2.3. Upper Arm Fat
        • 7.2.2.4. Abdominal Fat
        • 7.2.2.5. Thighs Fat
        • 7.2.2.6. Knee Fat
        • 7.2.2.7. Buttock Fat
        • 7.2.2.8. Others
      • 7.2.3. Global Injection Lipolysis by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Dermatology and Cosmetic Clinics
        • 7.2.3.3. Ambulatory Surgical Centers
      • 7.2.4. Global Injection Lipolysis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Injection Lipolysis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Injection Lipolysis: by Drug(USD Million)
  • Table 2. Injection Lipolysis Deoxycholic Acid , by Region USD Million (2016-2021)
  • Table 3. Injection Lipolysis Phosphatidylcholine , by Region USD Million (2016-2021)
  • Table 4. Injection Lipolysis Others , by Region USD Million (2016-2021)
  • Table 5. Injection Lipolysis: by Treatment Type(USD Million)
  • Table 6. Injection Lipolysis Facial Fat Deposits , by Region USD Million (2016-2021)
  • Table 7. Injection Lipolysis Submental Fat , by Region USD Million (2016-2021)
  • Table 8. Injection Lipolysis Upper Arm Fat , by Region USD Million (2016-2021)
  • Table 9. Injection Lipolysis Abdominal Fat , by Region USD Million (2016-2021)
  • Table 10. Injection Lipolysis Thighs Fat , by Region USD Million (2016-2021)
  • Table 11. Injection Lipolysis Knee Fat , by Region USD Million (2016-2021)
  • Table 12. Injection Lipolysis Buttock Fat , by Region USD Million (2016-2021)
  • Table 13. Injection Lipolysis Others , by Region USD Million (2016-2021)
  • Table 14. Injection Lipolysis: by End User(USD Million)
  • Table 15. Injection Lipolysis Hospitals , by Region USD Million (2016-2021)
  • Table 16. Injection Lipolysis Dermatology and Cosmetic Clinics , by Region USD Million (2016-2021)
  • Table 17. Injection Lipolysis Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 18. South America Injection Lipolysis, by Country USD Million (2016-2021)
  • Table 19. South America Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 20. South America Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 21. South America Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 22. Brazil Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 23. Brazil Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 24. Brazil Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 25. Argentina Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 26. Argentina Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 27. Argentina Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 28. Rest of South America Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 29. Rest of South America Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 30. Rest of South America Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 31. Asia Pacific Injection Lipolysis, by Country USD Million (2016-2021)
  • Table 32. Asia Pacific Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 33. Asia Pacific Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 34. Asia Pacific Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 35. China Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 36. China Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 37. China Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 38. Japan Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 39. Japan Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 40. Japan Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 41. India Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 42. India Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 43. India Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 44. South Korea Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 45. South Korea Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 46. South Korea Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 47. Australia Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 48. Australia Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 49. Australia Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 52. Rest of Asia-Pacific Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 53. Europe Injection Lipolysis, by Country USD Million (2016-2021)
  • Table 54. Europe Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 55. Europe Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 56. Europe Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 57. Germany Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 58. Germany Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 59. Germany Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 60. France Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 61. France Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 62. France Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 63. Italy Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 64. Italy Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 65. Italy Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 66. United Kingdom Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 67. United Kingdom Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 68. United Kingdom Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 69. Netherlands Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 70. Netherlands Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 71. Netherlands Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 72. Rest of Europe Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 73. Rest of Europe Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 74. Rest of Europe Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 75. MEA Injection Lipolysis, by Country USD Million (2016-2021)
  • Table 76. MEA Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 77. MEA Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 78. MEA Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 79. Middle East Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 80. Middle East Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 81. Middle East Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 82. Africa Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 83. Africa Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 84. Africa Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 85. North America Injection Lipolysis, by Country USD Million (2016-2021)
  • Table 86. North America Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 87. North America Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 88. North America Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 89. United States Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 90. United States Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 91. United States Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 92. Canada Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 93. Canada Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 94. Canada Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 95. Mexico Injection Lipolysis, by Drug USD Million (2016-2021)
  • Table 96. Mexico Injection Lipolysis, by Treatment Type USD Million (2016-2021)
  • Table 97. Mexico Injection Lipolysis, by End User USD Million (2016-2021)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Injection Lipolysis: by Drug(USD Million)
  • Table 108. Injection Lipolysis Deoxycholic Acid , by Region USD Million (2022-2027)
  • Table 109. Injection Lipolysis Phosphatidylcholine , by Region USD Million (2022-2027)
  • Table 110. Injection Lipolysis Others , by Region USD Million (2022-2027)
  • Table 111. Injection Lipolysis: by Treatment Type(USD Million)
  • Table 112. Injection Lipolysis Facial Fat Deposits , by Region USD Million (2022-2027)
  • Table 113. Injection Lipolysis Submental Fat , by Region USD Million (2022-2027)
  • Table 114. Injection Lipolysis Upper Arm Fat , by Region USD Million (2022-2027)
  • Table 115. Injection Lipolysis Abdominal Fat , by Region USD Million (2022-2027)
  • Table 116. Injection Lipolysis Thighs Fat , by Region USD Million (2022-2027)
  • Table 117. Injection Lipolysis Knee Fat , by Region USD Million (2022-2027)
  • Table 118. Injection Lipolysis Buttock Fat , by Region USD Million (2022-2027)
  • Table 119. Injection Lipolysis Others , by Region USD Million (2022-2027)
  • Table 120. Injection Lipolysis: by End User(USD Million)
  • Table 121. Injection Lipolysis Hospitals , by Region USD Million (2022-2027)
  • Table 122. Injection Lipolysis Dermatology and Cosmetic Clinics , by Region USD Million (2022-2027)
  • Table 123. Injection Lipolysis Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 124. South America Injection Lipolysis, by Country USD Million (2022-2027)
  • Table 125. South America Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 126. South America Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 127. South America Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 128. Brazil Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 129. Brazil Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 130. Brazil Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 131. Argentina Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 132. Argentina Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 133. Argentina Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 134. Rest of South America Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 135. Rest of South America Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 136. Rest of South America Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 137. Asia Pacific Injection Lipolysis, by Country USD Million (2022-2027)
  • Table 138. Asia Pacific Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 139. Asia Pacific Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 140. Asia Pacific Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 141. China Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 142. China Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 143. China Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 144. Japan Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 145. Japan Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 146. Japan Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 147. India Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 148. India Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 149. India Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 150. South Korea Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 151. South Korea Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 152. South Korea Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 153. Australia Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 154. Australia Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 155. Australia Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 158. Rest of Asia-Pacific Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 159. Europe Injection Lipolysis, by Country USD Million (2022-2027)
  • Table 160. Europe Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 161. Europe Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 162. Europe Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 163. Germany Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 164. Germany Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 165. Germany Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 166. France Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 167. France Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 168. France Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 169. Italy Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 170. Italy Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 171. Italy Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 172. United Kingdom Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 173. United Kingdom Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 174. United Kingdom Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 175. Netherlands Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 176. Netherlands Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 177. Netherlands Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 178. Rest of Europe Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 179. Rest of Europe Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 180. Rest of Europe Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 181. MEA Injection Lipolysis, by Country USD Million (2022-2027)
  • Table 182. MEA Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 183. MEA Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 184. MEA Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 185. Middle East Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 186. Middle East Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 187. Middle East Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 188. Africa Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 189. Africa Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 190. Africa Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 191. North America Injection Lipolysis, by Country USD Million (2022-2027)
  • Table 192. North America Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 193. North America Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 194. North America Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 195. United States Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 196. United States Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 197. United States Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 198. Canada Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 199. Canada Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 200. Canada Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 201. Mexico Injection Lipolysis, by Drug USD Million (2022-2027)
  • Table 202. Mexico Injection Lipolysis, by Treatment Type USD Million (2022-2027)
  • Table 203. Mexico Injection Lipolysis, by End User USD Million (2022-2027)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Injection Lipolysis: by Drug USD Million (2016-2021)
  • Figure 5. Global Injection Lipolysis: by Treatment Type USD Million (2016-2021)
  • Figure 6. Global Injection Lipolysis: by End User USD Million (2016-2021)
  • Figure 7. South America Injection Lipolysis Share (%), by Country
  • Figure 8. Asia Pacific Injection Lipolysis Share (%), by Country
  • Figure 9. Europe Injection Lipolysis Share (%), by Country
  • Figure 10. MEA Injection Lipolysis Share (%), by Country
  • Figure 11. North America Injection Lipolysis Share (%), by Country
  • Figure 12. Global Injection Lipolysis share by Players 2021 (%)
  • Figure 13. Global Injection Lipolysis share by Players (Top 3) 2021(%)
  • Figure 14. Global Injection Lipolysis share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Valeant Pharmaceuticals International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Valeant Pharmaceuticals International, Inc. (United States) Revenue: by Geography 2021
  • Figure 18. Allergan plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 19. Allergan plc. (Ireland) Revenue: by Geography 2021
  • Figure 20. Alma Lasers, Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Alma Lasers, Ltd. (Israel) Revenue: by Geography 2021
  • Figure 22. Cynosure, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cynosure, Inc. (United States) Revenue: by Geography 2021
  • Figure 24. Sciton, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Sciton, Inc. (United States) Revenue: by Geography 2021
  • Figure 26. Solta Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Solta Medical Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Lumenis Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 29. Lumenis Ltd. (Israel) Revenue: by Geography 2021
  • Figure 30. Syneron Medical Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Syneron Medical Ltd. (United States) Revenue: by Geography 2021
  • Figure 32. Apollo Cosmetic Clinics (India) Revenue, Net Income and Gross profit
  • Figure 33. Apollo Cosmetic Clinics (India) Revenue: by Geography 2021
  • Figure 34. Global Injection Lipolysis: by Drug USD Million (2022-2027)
  • Figure 35. Global Injection Lipolysis: by Treatment Type USD Million (2022-2027)
  • Figure 36. Global Injection Lipolysis: by End User USD Million (2022-2027)
  • Figure 37. South America Injection Lipolysis Share (%), by Country
  • Figure 38. Asia Pacific Injection Lipolysis Share (%), by Country
  • Figure 39. Europe Injection Lipolysis Share (%), by Country
  • Figure 40. MEA Injection Lipolysis Share (%), by Country
  • Figure 41. North America Injection Lipolysis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Valeant Pharmaceuticals International, Inc. (United States)
  • Allergan plc. (Ireland)
  • Alma Lasers, Ltd. (Israel)
  • Cynosure, Inc. (United States)
  • Sciton, Inc. (United States)
  • Solta Medical Inc. (United States)
  • Lumenis Ltd. (Israel)
  • Syneron Medical Ltd. (United States)
  • Apollo Cosmetic Clinics (India)
Additional players considered in the study are as follows:
VLCC Wellness (India) , Lutronic Corporation (South Korea) , Lynton Lasers Ltd (United Kingdom) , EL.En. S.p.A. (Italy) , Cutera Inc. (United States)
Select User Access Type

Key Highlights of Report


Aug 2022 167 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Injection Lipolysis Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Injection Lipolysis market is dominated by United States Players and may generate healthy valuation by 2027.
  • Growing Awareness Towards the fat Reduction Process
  • Increasing Population of Obese People
  • Increasing Demand for Non-Invasive Procedures
  • Demand for Cosmetic surgeries
dominated the Injection Lipolysis market. This is attributable to growing trend of "Many Women Prefer Undergoing Cosmetic Surgery Rather Than Changing Their Lifestyle"

Know More About Global Injection Lipolysis Market Report?